

In the Drawings:

Please substitute drawings sheets 1/15 through 15/15 with drawings sheets 1/29 through 29/29 affixed hereto as Appendix D. Drawing sheets 1/29 through 29/29 are fully supported by the original drawing sheets 1/15 through 15/15 and differ only with respect to formalities.

III. RESPONSE TO OFFICE ACTION DATED MAY 21, 2002

A. Support for the Amendments

The amendments to paragraphs 73 and 74 are supported by page 19 of the present specification and the Sequence Listing filed June 29, 2001.

Amended claims 14-17, 33 and 34 are presented in an amended form for the purposes of clarification, as follows:

Claim 14 is amended to include the additional requirement that each CTL epitope of the claimed polynucleotide is substantially free of sequences found naturally to flank that CTL epitope. Support for this feature is to be found *inter alia* in the final clause of pending claim 14 and in the description at paragraph 5 of the substitute specification filed on February 20, 2002 (i.e. corresponding to the description at page 2, lines 1-9 of the original specification).

Amended New claim 14 also clarifies the fact that it is the CTL epitopes, rather than the nucleic acids *per se*, that are either contiguous or spaced apart by an intervening sequence that does not comprise a methionine. Support for contiguous CTL epitopes is to be found *inter alia* in Figure 1 and Figure 5 of the application as originally filed. Support for the use of intervening sequences is to be found *inter alia* in Figure 5 of the application as originally filed, wherein a spacer sequence TS is positioned between the epitopes YPHFMPTNL and SGPSNTPPEI.